ArticleHuman pathology2011
Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.
Article in Human pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Evaluation of a Synthetic Polyethyleneimine Based Polymeric Vector forTurkish journal of pharmaceutical sciences · 2024Article
- Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer.PloS one · 2024Article
- Cxcl10 Chemokine Induces Migration of ING4-Deficient Breast Cancer Cells via a Novel Cross Talk Mechanism between the Cxcr3 and Egfr Receptors.Molecular and cellular biology · 2022Article
- Nuclear ING3 Expression Is Correlated With a Good Prognosis of Breast Cancer.Frontiers in oncology · 2020Article
- Identification of the inhibitor of growth protein 4 (ING4) as a potential target in prostate cancer therapy.Molecular and cellular biochemistry · 2020Article
- The essential role of tumor suppressor geneBioscience reports · 2019Review
- Overexpression of Inhibitor of Growth 4 Enhances Radiosensitivity in Non-Small Cell Lung Cancer Cell Line SPC-A1.Technology in cancer research & treatment · 2017Article
- Association between the expression of inhibitor of growth family member 4 and the progression of clear cell renal carcinoma.Oncology letters · 2017Article
- Miz1, a Novel Target of ING4, Can Drive Prostate Luminal Epithelial Cell Differentiation.The Prostate · 2017Article
- Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells.Breast cancer (Dove Medical Press) · 2016Article
- ING4 enhances paclitaxel's effect on colorectal cancer growth in vitro and in vivo.International journal of clinical and experimental pathology · 2015Article
- Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis.Cancer research · 2014Article
- ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth.Oncogene · 2014Article
- EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer.British journal of cancer · 2013Article
- Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy.Cancer gene therapy · 2012Article
- Effect of the tumor suppressor gene ING4 on the proliferation of MCF-7 human breast cancer cells.Oncology letters · 2012Article
- Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.BMC cancer · 2012Article
- Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density.Journal of cancer research and clinical oncology · 2012Article
- Inhibitor of growth-4 mediates chromatin modification and has a suppressive effect on tumorigenesis and innate immunity.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 4 countries.
Funding
Abstract
Inhibitor of growth 4 (ING4) is a candidate tumor suppressor gene that was shown to be deleted in 10% to 20% of breast cancers by array comparative genome hybridization analysis. We developed fluorescent in situ hybridization to detect the ING4 gene directly in the tissue samples on tumor tissue microarrays. We evaluated the ING4 gene status in 1033 breast cancer tissue samples and observed that ING4 was deleted in 16.5% (170/1033) of all breast cancers. ING4 deletion was significantly associated with Her2 overexpression: of the tumors with ING4 deletion, 23.8% (39/164) were human epidermal growth factor 2 (HER2) positive, as compared with 14.1% (115/814) of the tumors without ING4 deletion (P = .002). In addition, the tumors with ING4 deletion were more likely to belong to the HER2 molecular subtype (estrogen receptor negative/progesterone receptor negative/human epidermal growth factor positive) of breast cancer, compared with the other subtypes (28.4% HER2 versus 15.7% all, P = .002). ING4 deletion did not affect survival outcome of all patients with breast cancer (P = .797) or of the patients with HER2-positive tumors (P = .792). We conclude that ING4 deletion in breast cancer is relatively common, as 1 in 6 breast cancer harbors ING4 deletion. Furthermore, ING4 deletion is more prevalent in HER2-positive tumors, suggesting a functional antagonistic relationship between the ING4 tumor suppressor and the HER2 oncogene. These results sustain the view that ING4 is a tumor suppressor in breast cancer and suggest that ING4 deletion may contribute to the pathogenesis of HER2-positive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.